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Small molecule inhibitorsDue to many favourable attributes adenoviruses (Ads) are the most extensively used vectors for clinical gene
therapy applications. However, following intravascular administration, the safety and efficacy of Ad vectors
are hampered by the strong hepatic tropism and induction of a potent immune response. Such effects are
determined by a range of complex interactions including those with neutralising antibodies, blood cells
and factors, as well as binding to native cellular receptors (coxsackie adenovirus receptor (CAR), integrins).
Once in the bloodstream, coagulation factor X (FX) has a pivotal role in determining Ad liver transduction
and viral immune recognition. Due to difficulties in generating a vector devoid of multiple receptor binding
motifs, we hypothesised that a small molecule inhibitor would be of value. Here, a pharmacological approach
was implemented to block adenovirus transduction pathways. We developed a high throughput screening
(HTS) platform to identify small molecule inhibitors of FX-mediated Ad5 gene transfer. Using an in vitro fluo-
rescence and cell-based HTS, we evaluated 10,240 small molecules. Following sequential rounds of screening,
three compounds, T5424837, T5550585 and T5660138 were identified that ablated FX-mediated Ad5 trans-
duction with low micromolar potency. The candidate molecules possessed common structural features
and formed part of the one pharmacophore model. Focused, mini-libraries were generated with structurally
related molecules and in vitro screening revealed novel hits with similar or improved efficacy. The com-
pounds did not interfere with Ad5:FX engagement but acted at a subsequent step by blocking efficient intra-
cellular transport of the virus. In vivo, T5660138 and its closely related analogue T5660136 significantly
reduced Ad5 liver transgene expression at 48 h post-intravenous administration of a high viral dose
(1 × 1011 vp/mouse). Therefore, this study identifies novel and potent small molecule inhibitors of the Ad5
transduction which may have applications in the Ad gene therapy setting.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Adenoviruses have been developed, engineered and partially
optimised for use as gene therapy vectors, viral oncolytics and vac-
cines. Several features make them attractive tools for such a broad
range of applications including the relative ease of genetic manipula-
tion, large packaging capacity, transduction efficiency and high levelerms of the Creative Commons
which permits non-commercial
d the original author and source
: +44 141 330 5339.
. Baker).
60, University of Texas Health
29-3900, USA.
blished by Elsevier B.V. All rights retransgene expression. Furthermore, Ads can be produced at high ti-
tres under Good Manufacturing Practice conditions, an attribute key
for successful development in the biotechnology industry and for
clinical translation. As a result they are currently the most widely
used vector in clinical gene therapy protocols, with the majority of
studies based on Ad serotype 5 [1]. Nevertheless, despite the many
favorable characteristics and promising results of preclinical trials,
efficacy in the clinic has been variable indicating that the full transla-
tional potential of these viruses is yet to be reached.
There are several pitfalls which need to be overcome in order to
improve the viability of Ad5 as a therapeutic gene delivery vector
[2]. For many gene therapy targets such as disseminated cancers the
optimal route for targeting the multitude of micro-metastases is
intravascular delivery. However, the safety and efficacy of Ad5 follow-
ing intravascular administration are hampered by two major factors,served.
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liver, along with immune recognition of the virus [3–6]. A series of
complex host “off target” interactions define this inherent hepatic tro-
pism and immunogenicity. Pre-existing neutralising antibodies and
the resident liver macrophages, Kupffer cells, sequester a large propor-
tion of the viral load and contribute to the host inflammatory response
[5]. Virus binding to blood components such as erythrocytes [7,8], plate-
lets [9,10], complement [11] and coagulation factors [12,13] all impact
strongly on the ability of the virus to circulate. In recent years, several
studies have focused on the role of factor X (FX), a central component
of the coagulatory system, in determining the Ad tropism [14]. Upon
contact with the blood Ad5 transduction of the liver is mediated by a
direct high affinity interaction between the virus and FX [13]. The FX
γ-carboxylated glutamic acid domain binds to the hexon protein and
the FX serine protease domain tethers the Ad5:FX complex to heparan
sulphate proteoglycans (HSPGs) on the surface of hepatocytes, resulting
in subsequent cell binding and receptor-mediated virus internalisation
[12–16]. Crystallographic and cryoelectronmicroscopy techniques have
been employed to identify the key amino acid residues within the
hexon responsible for binding FX [17,18]. Generation of Ad5 vectors de-
void of FX-binding effectively ablated liver transduction in vivo [17,19].
Interestingly, recent work has also implicated an important role for FX
in the induction of viral innate immune and inflammatory responses
[18]. Genome wide transcriptional profile analysis in vivo revealed
significant differences in the genes activated by Ad5 and a FX-binding
ablated Ad5 vector [18]. In contrast to the parental vector, the non-FX
binding Ad5 failed to activate NFKB-dependant early response genes
encoding several Ad associated inflammatory cytokines and chemokines
[18]. Thismaybe related to the newly identified role for FX in the protec-
tion of Ad5 from attack by natural antibodies and complement [6]. In
contrast to studies in wild-type mice, FX coating of the virus was not
found to be essential for liver transduction in mice deficient in antibod-
ies, C1q and C4 [6].
It is therefore evident that a series of differential and sophisticated
host mechanisms exist which have important roles in determining Ad
tropism, immunogenicity and ultimately vector efficacy and safety in
vivo. Ideally, a vector could be administered intravascularly and bypass
its native tropism to selectively target the desired cells/tissues in the
absence of an immune response. Due to the complexity in the develop-
ment and generation of a vector devoid of multiple receptor binding
sites, one alternate approach was to develop a small molecule inhibitor
to block FX-mediated Ad5 transduction. Here we implemented a high
throughput strategy to screen a pharmacologically diverse library
of “drug-like” compounds in search of a compound capable of manipu-
lating the FX-mediated Ad5 transduction pathway.
2. Materials
Purified human blood coagulation FXwas purchased from Cambridge
Biosciences (Cambridge, UK). The Pharmacological Diversity Drug-like
Set was purchased from Enamine (Kiev, Ukraine). Hoechst 33342 and
propidium iodide were obtained from Sigma Aldrich (Poole, UK).
3. Methods
3.1. Ethics statement
All animal experiments were approved by the University of
Glasgow Animal Procedures and Ethics Committee and performed in
strict accordance with UK Home Office guidelines.
3.2. Cell lines, cell culture and virus production
A549 (human lung carcinoma ATCC CCL-185) and SKOV3 (human
ovarian carcinoma: ATCC HTB-77) cells were grown in RPMI 1640 medi-
um supplemented with 10% foetal calf serum, 2 mM L-glutamine and 1%penicillin–streptomycin (Invitrogen, Paisley, UK). HEK293 (human em-
bryonic kidney: ATCCCRL-1573) cellswere grown inDulbecco'sModified
Eagle'sMedium (DMEM; Invitrogen, Paisley, UK) supplementedwith 10%
foetal calf serum, 2 mM L-glutamine and 1% penicillin–streptomycin.
High titre stocks of recombinant E1/E3-deleted Ad5 were produced by
large-scale expansion of a plaque pure stock of Ad5 in HEK293 cells. Vi-
ruses were purified by CsCl gradient centrifugation. Viral particles (vp)
were determined by microbicinchoninic-acid assay (Perbio Science,
Cramlington, UK) using the formula 1 μg protein = 4 × 109 vp [20].
End-point dilution assays were performed to quantify plaque-forming
units (PFU)/ml. All preparations of Ad5 used in this study had similar
vp:PFU titre ratios of approximately 50:1.
3.3. Compound library
The Pharmacological Diversity Drug-like Set (Enamine, Kiev) library
consisted of 10,240 compounds preplated in columns 3 to 22 of 32 Ma-
trix 384-well plates as single compounds at a concentration of 10 mM in
100% DMSO. Each plate had an individual barcode and sample ID for
tracking purposes. Plates were sealed and compounds stored under
nitrogen (BOC, Glasgow, UK) at −20 °C. All compounds were assured
by the vendor (Enamine) to be at least 90% pure as assessed by liquid
chromatography–mass spectrometry andproton nuclearmagnetic reso-
nance spectrometry. Analogue compounds of the hits from the screen
were also purchased from Enamine. Briefly, the Pharmacological Diver-
sity Drug-like Set was designedwith the concept that active compounds
against orphan targets may have topological properties similar to
known small molecules (manuscript in preparation). That is, chemical
space of known drugs can be used as a restriction factor upon selection
of screening candidates for HTS campaigns against novel targets. To de-
sign the set, compounds from the Enamine stock collection (~1,000,000
compounds) were used. Using the program PASS (http://www.
pharmaexpert.ru/passonline/reference.php) over 3000 biological activi-
ties for every compound in the stock were predicted [21]. As a result
each compound has a “pharmacological profile” and any activity was
denoted in binary mode as either active or inactive. Next, profile cluster-
ing was performed irrespective of the compounds' chemical structure.
10,240 centroids from this clusterisation were selected. Absorption, dis-
tribution, metabolism, and excretion (ADME) properties of compounds
were predicted with QikProp (Schrodinger Inc.).
3.4. HTS assay
SKOV3 cells were seeded at a density of 1500 cells/well in 50 μl
complete media in 384 μ-clear flat bottom black plates (Greiner
bio-one, UK). Cells were tested prior to use to ensure that they were
mycoplasma free. All robotics protocol design, scheduling and execu-
tion were performed using Biomek Software (Beckman Coulter, USA),
SAMI Workstation EX Software (Beckman Coulter) and Biomek FXP
Laboratory Automation Workstation (Beckman Coulter). Compound
dilution plates (in serum free (SF) RPMI) were generated. Ad5GFP
was added to columns 2 to 23 of the compound dilution plate. Cells
in the assay plate were washed in SF media. 22.5 μl of SF media
was added to each well of the control columns 1, 2, 23 and 24 and
22.5 μl of SF media containing FX was added to each well in columns
3 to 22. Columns 1 and 24 contained the untreated control samples.
Columns 2 and 23 contained the test control samples. Into every
second well of columns 2 and 23, 2.5 μl of SF media containing FX
was added (final concentration of 10 μg/ml FX and 1% (v/v) DMSO
vehicle) and into every other well of those columns, 2.5 μl of SF
media was dispensed (−FX controls). 1000 vp/cell of Ad5 with/with-
out compound was added to the cells. The virus used in this assay
came from a single preparation of Ad5. Each compound was tested
in triplicate, with each replicate on a separate plate. All wells in
columns 3 to 22 had a concentration of 10 μM compound, 10 μg/ml
FX and 1% (v/v) DMSO. Plates were incubated at 37 °C for 3 h. After
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(v/v) penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine was
added to all wells. Assay plates were further incubated at 37 °C. 48 h
post-infection cells were fixed in 4% PFA for 15 min at room tempera-
ture. 10 μg/ml Hoechst 33342 and 10 μg/ml propidium iodide were
added to the cells and incubated at room temperature for 20 min.
Cells were washed in PBS before being imagedwith the In Cell Analyser
2000 (GE Healthcare, Pittsburgh, USA). A single image of the central
field of view in each well was captured using the 10× objective.
Imaging conditions were as follows, filter sets were matched to each
fluorophore; 350excitation (ex) nm and 455emission (em) nm for Hoechst
33342 nuclear staining, 490ex nm and 525em nm for GFP expression
and 579ex nm and 624em nm for propidium iodide non-viable nuclear
staining. To quantify the amount of GFP expression per viable cell, the
images were analysed using IN Cell Developer Toolbox V1.6 software
(GE Healthcare). This resulted in a numerical output enabling the calcu-
lation of results.
3.5. HTS data analysis
All test data were normalised to intraplate Ad5−FX, Ad5+FX and
vehicle controls and expressed as percentage inhibition of FX-mediated
Ad5GFP expression (% inhibition = (positive control − test com-
pound) / (positive control − negative control)). To evaluate the ro-
bustness of the assay we calculated the Z′ factor in initial optimisation
experiments [22]. The calculations were done according to the fol-
lowing formula: Z′ = 1 − ((3δpos + 3δneg) / (μpos−μneg)), where
δpos is the standard deviation for the Ad5+FX control, δneg is the stan-
dard deviation for the Ad5−FX control, μpos is the mean signal for the
Ad5+FX control and μneg is the mean signal for the Ad5−FX con-
trol. The signal to background ratio (S:B = μpos/μneg) was also cal-
culated. Any compounds causing greater than 75% inhibition of
FX-mediated Ad5GFP expression were selected for second round
screening analysis.
3.6. Analysis of Ad5 transduction in vitro
Cells were seeded in 96-well plates at a density of 2 × 104 cells/well
and incubated overnight at 37 °C. Cells were washed with PBS and
incubated with 1000 vp/cell Ad5lacz in SF medium in the absence or
presence of 10 μg/ml FX with DMSO, T5550585, T5424837, T5660138,
T5677956, T5660136 or T5572402 (Enamine) for 3 h at 37 °C. 100 μl
of complete medium containing 20% serum was added to the cells and
then incubated at 37 °C for a further 45 h. Cells were harvested by lys-
ing in 100 μl 0.2% Triton-X-100. β-Galactosidase was quantified using
Tropix Galacto-light Plus (Applied Biosystems, Warrington, UK) and a
Wallac VICTOR2 plate reader (PerkinElmer Life and Analytical Sciences,
Boston MA). β-Galactosidase activity was then normalised to total
protein content of the samples, measured by bicinchoninic acid assay
as per manufacturer's instructions, producing relative light units
per milligram protein (RLU/mg protein). In some cases data were
normalised to Ad5−FX and Ad5+FX controls and expressed as per-
centage inhibition of FX-mediated Ad5 expression. IC50 values were
calculated by fitting a 4-parameter logistic non-linear regression
model equation using MasterPlex ReaderFit analysis software.
3.7. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay
SKOV3 cells were plated at a seeding density of 2 × 104 in 96-well
plates and incubated at 37 °C overnight. Cells were incubated with
either DMSO or transduced with virus in the presence of 10 μM com-
pound. After 48 h the medium on the cells was replaced with 100 μl
complete medium and 15 μl of the MTT reagent. Cells were incubated
for 4 h at 37 °C, after which 100 μl of Solubilization Solution/Stop Mix
was added to each well and cells were incubated for a further 1 h at37 °C. The cell viability was measured as colour intensity using a
Wallac VICTOR2 plate reader (Wallac) at a wavelength of 570 nm
and which is directly proportional to the amount of live cells in the
sample.
3.8. Surface plasmon resonance (SPR) analysis of Ad5:FX binding
SPR was performed using a Biacore 2000 (GE Healthcare, London,
UK). Human FX was covalently immobilised on to the flowcell of a
CM5 biosensor chip by amine coupling according to the manufacturer's
instructions [12]. The immobilisation density was 500 response units.
Sensorgrams were generated at a flow rate of 30 μl/min using 10 mM
HEPES pH 7.4, 150 mMNaCl, 5 mM CaCl2, and 0.05% Tween-20 as run-
ning buffer and regeneration between injections with HEPES pH 7.4,
150 mM NaCl, 3 mM EDTA, and 0.05% Tween-20. Injections of 10 μM
compounds T5550585, T5424837, T5660138, T5677956, T5660136 or
T5572402 (Enamine) or an equivalent volume of DMSO in the presence
of Ad5 diluted in running buffer were passed over the chip. This was
followed by regeneration of the biosensor chip. DMSO subtracted
sensorgrams were generated and data analysed using Biacore 2000
Evaluation software.
3.9. Quantification of Ad5 colocalisation with the microtubule organising
centre (MTOC)
Cells were seeded in 8-well chamber slides at 4 × 104 cells/well
and incubated at 37 °C overnight. Cells were washed with PBS and in-
cubated with 1 × 104 vp/cell of fluorescently-labelled Ad5 in 150 μl
SF media for 1 h on ice in the absence or presence of 10 μg/ml FX
with or without 10 μM pharmacological compound. Cells were incu-
bated at 37 °C for 180 min prior to washing and fixation. Localisation
of Ad particles at the MTOC was characterised by staining cells using
a polyclonal rabbit pericentrin antibody (1:200 dilution: Abcam,
Cambridge, UK) [16]. Cells were imaged using a Zeiss confocal micro-
scope (LSM510). Colocalisation of Ad5 with the MTOC was quantified
by visually assessing the percentage of cells with Alexa488-virus and
pericentrin co-staining. Data were averaged from five microscope
fields of view (40× objective) per experimental condition.
3.10. Circular dichroism analysis
Spectraweremeasured in quartz cells of 1 mmpath length in a Jasco
J-810 spectropolarimeter. Virus particles were measured using a
concentration of 1 × 108 vp/sample in the presence of 10 μM T138,
10 μM T136 or an equivalent volume of DMSO in PBS. Samples were
heated from 35 °C to 55 °C at increments of 2 °C using a Peltier device.
Samples were allowed to equilibrate for 2 min at each temperature
prior to measurement.
3.11. In vivo studies
Mice were injected via lateral tail vein injection with 1 × 1011 vp/
mouse of Ad5 expressing a luciferase transgene in the absence or
presence of 0.1% DMSO, 10 μM compound T5660138 or T5660136 in
a final volume of 200 μl PBS or PBS alone. 48 h post-administration
mice were injected subcutaneously with 300 μl of XenoLight D-Lucif-
erin (Caliper, Life Sciences, Hopkinton, MA, USA). Mice were subject
to whole body bioluminescence quantification (IVIS Spectrum, Cali-
per Life Sciences). Luciferin activity was measured using the IVIS
Imaging System (IVIS Spectrum, Caliper) and expressed as average
radiance (photons per second per centimetre squared per steradian
(p/s/cm2/sr)). Blood samples were taken from mice at 48 h and
serum separated from whole blood using a BD SST Microcontainer
with clot activator (BD Diagnostics, Oxford, UK). Serum transaminases,
aspartate aminotransferase (AST) and alanine aminotransferase (ALT),
were quantified from 80 μl serum by the Veterinary Diagnostic Service
Fig. 1. The HTS methodology. (A) SKOV3 cells were incubated with 1000 vp/cell of
Ad5GFP in the absence or presence of FX. 48 h post-infection cells were fixed and
stained with Hoechst 33342, imaged using the IN Cell Analyzer 2000 and analysed
using the IN Cell Developer Toolbox. Nuclei, cells and GFP expression were segmented
based on their staining, size, shape and intensity. The outline of each of these parame-
ters was highlighted using the software bitmap overlay; the nuclei are shown in blue,
the cells in pink and the GFP in green. (B) Cells were infected with 1000 vp/cell of Ad5
in the absence or presence of 40 μM T0501-7827 (Enamine, Ukraine), a cytotoxic com-
pound. After 48 h cells were fixed and stained with Hoechst 33342 and propidium io-
dide, imaged and analysed. Non-viable cells were segmented based on propidium
iodide staining. Once parameters were defined, the IN Cell Developer Toolbox was
used to calculate the number of viable cells. 10× magnification, scale bars = 50 μm.
(C) Trellis heat map of the assay plate highlighting the plus (red) and minus (green)
FX control conditions. (D) SKOV3 cells were incubated with 1000 vp/cell of Ad5GFP
in the absence or presence of FX and GFP transgene expression was quantified at
48 h using the IN Cell Developer Toolbox. GFP expression was normalised to the num-
ber of viable cells. *p b 0.05 as compared to Ad5−FX control.
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with PBS and their livers and spleens used for immunohistochemistry
on frozen tissue.
3.12. Luciferase immunofluorescence
Immunohistochemistry for luciferase expression was achieved by
staining 4 μm liver or 6 μm spleen frozen sections with a mouse
anti-luciferase (Luci17; Santa Cruz Biotechnology, Heidelberg, Germany)
IgG1, used at a final concentration of 1.33 μg/ml. Sections were fixed
with ice-cold acetone at −20 °C for 10 min and allowed to air dry for
1 h. Endogenous avidin/biotin activity was blocked using a commercial
kit (Vector Laboratories, Peterborough, UK). Staining was performed
using theM.O.M Fluorescein Immunodetection kit (Vector Laboratories).
Fluorescencewas visualised using anOlympus BX60fluorescencemicro-
scope (×40 magnification) and images acquired using Cell'M software
(Olympus, London, UK). An isotype control antibody was used at identi-
cal final concentrations. Images were processed to reduce background
using ImageJ and adjustments were applied equally to all compared
images. Quantification of Alexa-488 positive regions was calculated
as follows: at least 10 separate images (3 animals/group) were
processed under binary, selecting find maxima. Noise tolerance
was set uniformly at 10 and output set to identify single pixels whilst
excluding edge maxima. Data is presented as luciferase expression/×40
field of view.
3.13. Statistical analysis
Results presented are representative data from a minimum of
three separate experiments with at least three experimental repli-
cates per group, unless otherwise stated. High throughput screening
of the entire Pharmacological Diversity Drug-like Set compound li-
brary was performed once but all hits were subjected to subsequent
analysis as indicated. Where necessary, data were normalised by
logarithmic transformation. Data are represented as mean ± stan-
dard error of the mean (SEM). Statistical significance was calculated
using 2-sample, 2-tailed student's t-tests or one way ANOVA followed
by Dunnett's post-hoc test. p b 0.05 was considered statistically
significant.
4. Results
4.1. HTS for inhibitors of FX-mediated Ad5 transduction
It has been previously described that co-incubation of Ad5 with
physiological levels of FX (10 μg/ml) causes a substantial increase in
Ad5 transduction in vitro and in vivo compared to Ad5 alone [13,16].
In this study, initial optimisation and validation experiments were
performed to convert this frequently employed in vitro assay into a
high throughput cell-based screen in order to test a diverse library of
compounds for their ability to inhibit FX-mediated Ad5 transduction.
The assay was adapted to a 384-well format employing SKOV3 cells, a
cell line susceptible to FX-mediated Ad infection [16], and anAd5 vector
expressing a GFP transgene. 10,240 low molecular weight compounds
from the Pharmacological Diversity Drug-like Set were screened at a
concentration of 10 μM in the presence of 10 μg/ml FX in triplicate. At
48 h post-infection cells were fixed and stained with Hoechst 33342
and propidium iodide, then imaged and analysed using the In Cell
Analyzer 2000 and Developer Toolbox V1.6 software (Fig. 1A and B).
Ad5GFP expression was treated as the primary readout, with clear
MIN (minus FX) and MAX (plus FX) controls on each plate, providing
a broad signal window in which to identify compounds that blocked
Ad5 transduction in the presence of FX (Fig. 1A, C and D). In order to
prevent skewing of results due to compound toxicity non-viable cells
were discarded from the analysis (Fig. 1B) and a measure of GFP inten-
sity per viable cell perfield of viewwas calculated. The 1%DMSO vehiclecaused no effect on assay performance (Supplementary Fig. 1A and B).
Test data were normalised to plus and minus FX control conditions
and data represented as percentage inhibition of FX-mediated
Ad5GFP expression. The suitability of this assay for a HTS was veri-
fied in initial experiments, having a signal to background ratio of
29.82 ± 3.93-fold and an average Z′ factor > 0.5 [22]. A plot of the
percent inhibition from the 32 sets of assay plates classified by
plate row and the plate row median data value indicated that the
assay was well behaved and the majority of compounds were inac-
tive and exhibited activity levels similar to the plus FX control
conditions (i.e. ≤0% inhibition of FX-mediated Ad5 gene transfer)
(Fig. 2A and B). Hits were identified as those causing >75% inhibi-
tion of FX-mediated Ad5 transduction. From the primary screen
and secondary rounds of screening 17 compounds (0.16% of initial
library) were identified (Fig. 2C and D). Upon exclusion of com-
pounds causing toxicity, non-reproducible effects or those with
structural features which may exhibit bias towards compound pro-
miscuity, three hit compounds (0.029% hit rate) were selected for
detailed analysis.
Fig. 2. Candidate screen hits. Cells were incubated with 1000 vp/cell of Ad5GFP in the
absence or presence of FX plus 10 μM compound (Pharmacological Diversity Drug-like
set — 10,240 in total). At 48 h the cells were fixed and stained, then screened for their
ability to inhibit FX-mediated Ad5GFP expression. Data was normalised to minus and
plus FX control conditions and represented as percentage inhibition. (A) Graphical sum-
mary of the HTS data categorised by plate rows A to P. Each row is separated by colour.
(B) Plot of plate row median percentage inhibition of FX-mediated Ad5GFP expression
showing the median trendline. (C) Each dot represents an individual compound. Com-
pounds causing >75% inhibition, as shown above the dashed line, are highlighted in
blue. (D) Schematic review of the HTS process.
Fig. 3. Identification of the primary hit compounds. (A) Cells were infected with
1000 vp/cell of Ad5 in the absence or presence of FX and 10 μM compounds T138,
T837 and T585. Transgene expression was measured 45 h post-infection. Results
were adjusted to ±FX controls. (B) Cell viability was assessed after 48 h
co-incubation with each compound. Error bars represent SEM (n = 4/compound).
(C) Chemical structures of T138, T837 and T585. (D) (i) T585 (green) with T138
(blue) and (ii) T138 (blue) with T837 (red). Zones of high topological identity are
highlighted. (iii) Structural alignment of all three hits. Common minimal
pharmacophore core is shown: 5-membered heterocycle with hydrogen bond
acceptor and aromatic feature linked to a bulky lipophilic feature.
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T5424837 and T5550585
The three hit compounds identified were T5660138 (abbreviated to
T138), T5424837 (T837) and T5550585 (T585). All three compounds
ablated FX-mediated Ad5 transduction, in the absence of cytotoxicity
(Fig. 3A and B). Compounds T138, T837 and T585 possess several com-
mon structural features (Fig. 3C and D). Compounds T585 and T138
share a similar 3-phenyl-5-methlene-1,2,4-oxadiazole moiety, whereas
T138 and T837 have similar substituted condensed heterocyclic sys-
tems bridged to a 5-membered heterocyclic ring via two atom linkers
(Fig. 3C and D). Hence, compound T138 has features that overlap with
both T585 and T837. In order to align all three molecules simultaneous-
ly, a pharmacophore hypothesiswas formed (Fig. 3D). Theminimal core
can be defined as two heterocyclic moieties bridged via a 1–2 atom
linker. The first moiety is a 5-membered electron rich heterocycle
which may serve as a H-bond acceptor as well as a participant in van
derWaals contacts. The secondmoiety, larger by volume, is a lipophilic,
condensed heterocycle system that may serve as a bulk van der Waals
contributor and the quinazoline and 1,3-benzodiaxane of T138 and
T837, respectively, along with the 4-nitro-3,5-dimethyl-1,2-pyrazole
of T585 are putative representatives. Therefore the pharmacophore
model was defined as 5-membered heterocycle with hydrogen bond
acceptor and aromatic features linked to a bulky lipophilic feature.
4.3. Activity of T138, T837 and T585 and compound analogues
Based on the established pharmacophore model, for every prima-
ry hit a follow-up library was designed. Compounds that resemble the
minimalistic core with various substitutions on the periphery were
identified in stock collections. An additional 28 compounds were
selected and preliminary structure activity relationship analysis was
performed using this follow-up library. Several modifications to the
parental scaffold decreased the ability to block FX-mediated Ad5transduction (Supplementary Figs. 2, 3 and 4). Screening results of
the follow-up library also revealed novel hits with similar or im-
proved activity. In an attempt to rank the analogue compounds
based on inhibition and potency, the IC50 of the three parent com-
pounds T138, T837 and T585 and the most active analogues were de-
termined. All compounds had IC50 values below 5.5 μM (Fig. 4). Data
revealed compound T136, ameta-chlorine substituted analogue of the
parent, had the most potent effect on FX-mediated Ad5 transduction,
having a 4-fold improved IC50 of 1 μM compared to 4.01 μM for T138
(Fig. 4A). Similarly with regard the T585 compound family the substi-
tution of the chlorine from a meta to a para position was well tolerat-
ed, as shown by the enhanced activity of compound T402 (Fig. 4B).
Finally, compound T956 caused the greatest level of inhibition at
the highest concentration of 10 μM, despite having an extra benzyl
ring to its parent compound T837 (Fig. 4C). These findings validate
the suggested pharmacophore model and initial hit compounds.
4.4. Active compounds do not interfere with Ad5:FX complex engagement
but disrupt a later step of the transduction pathway
A recent study by Xu et al. has shown that FX coating the Ad5 hexon
can in fact shield the virus from attack from the classical complement
system, thereby protecting the virus from neutralisation in the blood
[6]. Therefore it was important to investigate whether the compounds
were interfering with direct Ad5:FX complex engagement. To examine
if the compounds hindered Ad5 binding to FX, SPR analysis was
performed. 10 μM compound or an equivalent volume of DMSO was
Fig. 4. IC50 evaluation of hits and compound analogues. Cells were infected with Ad5 in
the absence or presence of FX plus 0.1, 0.5, 1, 5 or 10 μM (A) T138, (B) T585 or (C) T837
and chemically related compounds. Transgene expression was measured after 48 h.
Data was normalised to minus and plus FX control conditions and represented as per-
centage inhibition. Error bars represent SEM (n = 4/compound). The IC50 values for
each of the compounds were calculated by fitting a 4-parameter logistic non-linear
regression model equation using MasterPlex ReaderFit analysis software.
Fig. 5. Compounds act post Ad5:FX engagement (A) Sensorgrams of Ad5 in the pres-
ence of 10 μM compound or an equivalent volume of DMSO injected over FX for
~200 s at a flow rate of 30 μl/min. Sensorgrams are subtracted for blank injections.
(B) A549 cells were infected with Ad5±FX and μM compound and transgene expres-
sion was measured at 48 h. (C) A549 cells were incubated with 10,000 vp/cell of
Alexa488-labelled Ad5±FX and 10 μM compound for 1 h at 4 °C, followed by incuba-
tion at 37 °C for 180 min prior to staining for the MTOC marker pericentrin. Complete
colocalisation of Ad5 with pericentrin was calculated by analysing at least 5 separate
40× microscope fields per experimental condition. *p b 0.05 as compared to−FX con-
ditions or #p b 0.05 as compared to −FX.
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chip (Fig. 5A). When the Ad5 and DMSO control was passed over FX,
there was an increase in response units (up to ~60 RU), indicating Ad5
binding to FX. When Ad5 in the presence of each of the compounds
was passed over the chip, there was a similar increase in response
units. This suggests that the incubation of Ad5 with the transduction in-
hibitors does not interfere with Ad5 binding directly to FX. Next, we
examinedwhether the compounds could blockAd5 transduction viadif-
ferent established routes of Ad5 cell engagement and subsequent entry.
The CAR pathway was therefore assessed, in addition to FX-mediated
transduction. A549 cells were used as they express significant levels of
CAR and are also susceptible to FX-mediated Ad5 infection [16]. Under
control conditions, Ad5 transduction was significantly increased in
the presence of FX (~6-fold) (Fig. 5B). All compounds ablated Ad5 trans-
duction in the absence and presence of FX (Fig. 5B). This data demon-
strated the capability of the six compounds to inhibit both CAR and
FX-mediated Ad5 transduction in vitro. Subsequently, effects of the com-
pounds on Ad5 intracellular transport were investigated. Alexa-488
fluorescently labelledAd5 transport to theMTOCwas assessed in the ab-
sence and presence of 10 μM compound. Intracellular trafficking was
disrupted by each of the inhibitors (Fig. 5C). Instead of forming a punc-
tate localisation at the MTOC [16], virus localisation was diffuse in the
perinuclear region in the presence of each of the compounds. When
the percentage of cells with which the virus particles colocalised with
the MTOC was quantified, colocalisation was significantly reduced
with all inhibitors (Fig. 5C). These data indicate that in the presence of
the compounds post-entry intracellular trafficking of Ad5 to the nucleus
was disrupted.4.5. T138 and its analogue T136 decrease Ad5 transduction in vivo
without the elevation of toxicity markers
As T138 and T136 possess structural features common to both the
other two families (T837 and T585) these compounds were tested in
vivo to investigate whether the compounds decreased Ad5 liver
transduction. Prior to in vivo testing, we investigated if the com-
pounds were interfering with the stability of the viral particles. Circu-
lar dichroism (CD), a method for examining the extent and rate of
structural changes of a protein [23], was used to assess the effect of
incubation of 10 μM compound with the virus (Supplementary Fig.
5). CD spectra analysis indicated that for Ad5+T138 the mid-point
of protein unfolding occurred at ~45 °C as opposed to ~47 °C in the
case of Ad5+DMSO control and Ad5+T136 conditions (Supplemen-
tary Fig. 5). As this modest effect of T138 on virus stability occurred
above temperatures relevant to our assays (37 °C), and T136 had no
effect on thermostability of Ad5, it was concluded that the com-
pounds were not affecting the stability of the virus used in this
study. For in vivo experimentation, MF1 mice were injected intrave-
nously with a high dose of 1 × 1011 vp/mouse of Ad5 luciferase or
Ad5 which has been preincubated with 10 μM T138, 10 μM T136 or
an equivalent volume of the vehicle. Luciferase transgene expression
was visualised by whole-body bioluminescence imaging and
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liver as evidenced by the high levels of luciferase expression visually
and quantitatively assessed by bioluminescence imaging at 48 h post-
injection (Fig. 5A and B). There was no significant difference observed
in the Ad5 plus DMSO control group, indicating that the vehicle did
not cause an effect on Ad5 transduction in vivo (Fig. 5A and B). How-
ever, in the presence of T138 and T136 there were 6.7-fold and
4.6-fold decreases respectively in luciferase expression compared to
Ad5 and Ad5 plus DMSO control conditions (Fig. 5A and B). In addi-
tion, immunohistochemistry was performed for luciferase transgene
expression in frozen liver and spleen sections (Fig. 6C, D and Supple-
mentary Fig. 5). In concordance with the bioluminescent imaging
data, a significant reduction in luciferase transgene expression in
the livers of animals treated with Ad5 in the presence of T136 and
T138 was observed. This indicates that these two closely related com-
pounds exhibit activity in vivo, decreasing hepatic transduction of
Ad5. There was no significant difference between the groups in the
levels of luciferase transgene expression in spleen sections as shown
by immunofluorescence analysis (Fig. 6D and Supplementary Fig. 6).
The elevation of serum transaminases, such as AST and ALT levels can
be an indicator of acute toxicity in vivo. Therefore we analysed serum
samples taken from mice 48 h post-injection of virus ± compound
for the levels of AST and ALT to see if the compounds were having a
toxic side effect. We found no significant difference in either serum
transaminase between the Ad5 control, Ad5+DMSO, Ad5+T138 or
Ad5+T136 groups of animals.Fig. 6. Effect of hit compounds on Ad5 transduction in vivo. (A) Luciferase expression
visualised by whole-body bioluminescence imaging 48 h after intravascular administra-
tion of 1 × 1011 vp/mouse Ad5 alone, Ad5 in the presence of 10 μM T138, 10 μM T136
or DMSO in 200 μl PBS or PBS alone in MF1 mice. (B) Luciferase expression as assessed
by whole-body bioluminescence imaging was quantified at 48 h. (C) Luciferase expres-
sion in frozen liver sections (5 μm) was detected by immunofluorescence. Scale bar =
50 μm. (D) Luciferase expression in frozen liver and spleen sections were quantified
using Image J software by analysing at least 10 separate images from 40× microscope
fields per experimental condition. *p b 0.05 as compared to Ad5 control conditions.
(E and F) Serum transaminases, (E) aspartate aminotransferase (AST) and (F) alanine ami-
notransferase (ALT) were quantified 48 h postinjection of 1 × 1011 vp/mouse.5. Discussion
Adenoviruses continue to hold great promise for a vast number of
gene, viral and vaccination applications. However, virus binding to
host factors results in liver sequestration and potent innate immune
and inflammatory responses. This compromises vector efficacy and
is of clear concern for the successful use of Ads in the clinical setting.
This study focused on developing a small molecule inhibitor approach
to block Ad transduction mediated by FX, a key host determinant of
the hepatic tropism and viral immune recognition [13,18].
Improvements in the understanding of Ad infection pathways
in vitro and key in vivo tropism determining interactions have allowed
the design of assays with more realistic and relevant parameters for
the identification of new drugs [13,23]. Recently it was found that spe-
cies D Ad37 infection causes epidemic keratoconjunctivitis by binding
of the Ad fibre knob protein to glycoproteins containing two terminal
sialic acidmoieties on the surface of epithelial cells in the cornea or con-
junctiva [24]. This finding led to Spjut et al. synthesizing tri- and tetra-
valent sialic acid compounds which effectively block Ad37 infection of
human ocular cells. SPR and crystallography techniques demonstrated
that the trivalent sialic acid conjugate, ME0322, binds directly to the
sialic acid-binding sites in the fibre knob, with similar affinity to GD1a
hexasaccharide, and is a potent inhibitor of Ad37 infection [25]. A sepa-
rate study reported the use of multivalent sialic acid constructs and the
development of “molecular wipes” for the topical treatment of Ad in-
duced epidemic keratoconjunctivitis [26]. These studies highlight the
current advancements in pharmacological inhibitory agents for use
against Ads from species D, progresswhich is largely due to the increas-
ing knowledge of Ad cell/organ interaction mechanisms.
Studies have shown that once the virus comes into contact with the
bloodstream FX is the major mediator of Ad liver transduction [13,14].
An array of simple anddiverse assays exists to studyAds andmanipulate
their interactions in vitro. In this study the FX-mediated Ad5 transduc-
tion pathway and routinely used cell-based protocols were exploited
to design a unique and robust Ad5 fluorescence reporter gene- and
cell-based HTS. It was hypothesised that identification of an inhibitor
of Ad transduction in the presence of FX using a relevant in vitro
set-up within a time frame sufficient to allow the key steps of infection
to occur (48 h), could have potential in an in vivo setting. The assay de-
veloped in this study is highly adaptable. For example a fluorescently-
labelled virus could be employed to investigate inhibitors or enhancers
of cellular binding or stages of the post-entry infection process. As the
assay has an easilymeasured readout it is a useful and rigorous approach
for the discovery of novel compounds that interfere with Ad infection
processes. For instance, a number of the compounds screened in this
assay caused a substantial enhancement of FX-mediated Ad5GFP ex-
pression, with compounds enhancing Ad5 gene transfer by up to
10-fold (Fig. 2C). In the cancer gene/viral therapy setting, compounds
which increase the Ad5 transduction capability immediately after local-
ised injection may be an attractive option for improved treatment of
solid tumours. This type of strategy could also be adapted for the treat-
ment of cardiovascular diseases, via coating stents with the Ad:FX:com-
pound complex to improve direct virus uptake in the vessel wall.
Investigation of potential Ad transduction enhancers identified from
this screen certainly warrants further study.
Previously the generation of compounds in screening libraries
was directed by chemical structures and selectivities rather than on
pharmacological properties. In this regard, in vitro affinities were
optimised at the potential expense of solubility, metabolic stability
and permeability properties and often compounds which appear to
be promising lead candidates are not always suitable for further me-
dicinal chemistry exploration which precludes their progression [27].
Screening libraries of compounds with drug-like properties is now
seen as preferable, possessing improved ADME and toxicity profiles.
Design of the Pharmacological Diversity Drug-like Set was based on
pharmacological features rather than on the chemical structure of
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itive hits identified (T138, T585, T837 (0.029% confirmed hit rate)) as
efficiently ablating FX-mediated Ad transduction were found to pos-
sess common structural features, fitting into the one pharmacophore
model. Moreover, the fact that T138 had similar features to both T585
and T837 adds confidence to the reliability of the experiment and screen-
ing validity. Importantly the effects of these compounds occurred in
the absence of any cytotoxicity, and the lack of toxic signatures can be
an important factor for downstream medicinal chemistry. This initial
pharmacophore model was further validated by the screening of ana-
logues and the identification of the new hits T136, T402 and T956, with
low micromolar potency. The enhanced IC50 values for several of the
analogues compared to the parent compound provide a proof of principle
that the characteristics of these compounds can be improved and thus
help to certify the structures as a starting point for the development of
such a small molecule inhibitor.
The recent work by Xu et al., showing the ability of FX to protect
the virus from attack by natural antibodies and complement, may
alter the way we design liver detargeting strategies for intravascular
gene therapy applications [6]. The compounds identified here, do
not hinder the Ad5:FX interaction but are effective at blocking a
later step of the transduction pathway. This may be advantageous in
that the virus would still acquire the protective FX coat thus evading
activation of immune pathways whilst still avoiding transgene ex-
pression mediated via this pathway. Alternatively the high through-
put screen could have been designed differently to look more
specifically at blocking only FX-mediated Ad transduction i.e. search
for inhibitors of Ad5:FX complex binding to the cell surface. There
are several ways such an assay could be designed, such as employing
SPR to screen compounds for those which blocked Ad5:FX binding, or
if a cell-based assaywas preferablemeasuring the effect of compounds on
fluorescently-labelled Ad5 binding in SKOV3 cells. Potent compound ef-
fects in vitro do not necessarily translate in the in vivo setting [28]. How-
ever in this instance, in vivo T138 and its closely related analogue T136
significantly reduced transgene expression at 48 h post-intravenous ad-
ministration of a high viral dose (1 × 1011 vp/mouse). This dose of virus
was chosen as it was previously demonstrated to cause high levels of
liver transduction inmice [19], thereby providing a clearmeasure of com-
pound effect. The activity shown by T138 and T136 in vivo was a very
promising result and this biological effect signifies the translational po-
tential of the compounds.
It would be of significant interest to study the effect of these inhibi-
tors on the hepatic uptake of different FX-binding serotypes and to in-
vestigate their influence on the retargeting capability of the vector. It
may be that the compounds successfully decrease Ad liver transduction
but allow for transgene expression of a modified vector in target cells/
tissues mediated via an alternate receptor e.g. integrin-mediated trans-
duction. Biodistribution studies could be performed by coincubation of
compound with an integrin targeted vector such as Ad5RGD4C, which
has been genetically engineered to contain a αv integrin binding ligand
in the HI loop [29,30], to assess effects on vector transduction. Further-
more, it would be of worth to investigate if blocking the FX pathway
using this small molecule inhibitor approach would alter the FX associ-
ated innate and inflammatory immune response. Comparing the early
immune response post-administration of Ad5 in the presence of T136
and T138with that following delivery of anAd5 FX-binding ablated vec-
tor alone could have value. In addition, the compounds identified in this
studymay also function as an anti-viral agent in the case of disseminat-
ed adenovirus infections. Ads have emerged as a significant pathogen
associated with high morbidity and mortality in immunocompromised
individuals (e.g. sufferers of hereditary immune deficiencies, AIDS
patients, haematopoietic stem cell transplant recipients undergoing im-
munosuppressive treatment).Whilst in healthy individuals Ad infection
ismostly self-limiting, in the immunocompromised host Ads exploit the
impaired immunological response and can become invasive causing
prolonged, severe and even life threatening disease. There are however,currently no formally approved selective antiviral agents available
that treat Ad infection thus these compounds may have potential in
the development of a novel anti-adenoviral agent.
To conclude, we propose the optimisation and development of
the compounds identified in this study, in particular T138 and T136,
which cause a potent effect in vitro and a substantial reduction in Ad5
gene transfer in vivo, as a novel strategy to prevent FX-mediated Ad5
transduction for gene therapy applications.Acknowledgements
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